BACKGROUND: L-type Ca V 1.2 channels play crucial roles in the regulation of blood pressure. Galectin-1 (Gal-1) has been reported to bind to the I-II loop of Ca V 1.2 channels to reduce their current density. However, the mechanistic understanding for the downregulation of Ca V 1.2 channels by Gal-1 and whether Gal-1 plays a direct role in blood pressure regulation remain unclear.
H
ypertension is a leading cause of cardiovascular diseases such as coronary heart diseases and stroke. 1, 2 Smooth muscle hypercontractility is one of the major contributing factors of high blood pressure. 3 The molecular defects or dysregulation in the mechanics of excitation-contraction coupling in smooth muscles generally contribute significantly to cardiovascular disease phenotypes. The L-type Ca V 1.2 calcium channels serve as the major pathway of Ca 2+ influx to trigger smooth muscle contraction, 4 and smooth muscle-specific deletion of Ca V 1.2 channels in mice abolished the development of myogenic tone and drastically reduced arterial blood pressure, 5 validating the central role that Ca V 1.2 channels play in regulating blood pressure.
The Ca V 1.2 channel is a hetero-oligomeric surface protein complex comprising a pore-forming α 1C subunit and auxiliary α 2 δ and β subunits, 6 and conducts Ca 2+ across the plasma membrane after it opens in response to membrane depolarization. 7 The α 1C subunit (Ca V 1.2) confers unique biophysical and pharmacological properties on the Ca V 1.2 channel, whereas the accessory subunits are mainly involved in anchorage, trafficking, and posttranslational modification. 8 The Ca V 1.2 is composed of 4 homologous transmembrane domains (I-IV), the cytoplasmic N terminus, C terminus, and the loops linking the domains. The I-II, II-III, and III-IV cytoplasmic loops contain important motifs that bind various proteins with modulatory functions. Of note, the Ca V β subunit bound to the α 1C subunit-interacting domain (AID) within the I-II loop regulates channel gating and voltage-dependent inactivation. 9 More importantly, coexpression of the Ca V β subunit was reported to promote the trafficking of Ca V 1.2 to the plasma membrane by preventing their degradation via the endoplasmic reticulum-associated degradation (ERAD) pathway. 10 ERAD degradation is a sophisticated quality-control mechanism that removes terminally misfolded or unassembled polypeptides from the endoplasmic reticulum (ER) lumen and lipid bilayer through the process of retrotranslocation, and ultimately results in their degradation by the proteasome.
We recently reported a novel Ca V 1.2-interacting partner, galectin-1 (Gal-1), that reduced the current density of Ca V 1.2 channels by binding to the C-terminal end of exon 9, downstream of the AID domain. 11 Gal-1, a member of the family of carbohydrate-binding proteins, 12 is a small protein with diverse functions, and it plays a role in tumor progression, inflammation, and T-cell immune disorders. 13 Other reports showed that Gal-1 was able to modulate the differentiation, proliferation, and migration of smooth muscle cells.
14 In Gal-1 knockout mice (Lgals1 -/-), increased pulmonary pressure was induced by acute hypoxia 15 and blood pressure was elevated by pregnancy in female mice from embryonic day 17.5, 16 indicating the possible involvement of Gal-1 in hypertension, but the mechanisms are unknown. In contrast, here, we identified Gal-1 as a negative regulator of vascular Ca V 1.2 channel by competitively disrupting Ca V 1.2-Ca V β interaction and promoting Ca V 1.2 degradation. It is important to note that disruption of the Ca V 1.2-Gal-1 interaction by a Tat-e9c peptide or overexpression of Gal-1 in smooth muscle by AAV5-Gal-1 resulted in the modulation of blood pressure in rats.
METHODS
The reagents that support the findings of this study are available from the corresponding author on request.
For details on methods such as electrophysiology, coimmunoprecipitation (co-IP), immunostaining, and confocal microscopy, blood pressure measurements by tail-cuff or telemetry, and pressure myography, please refer to the online-only Data Supplement. Plasmids, primers, and antibodies used in this study are listed in Tables I through IV 
Clinical Perspective
What Is New?
• Galectin-1 promotes the proteasomal degradation of Ca V 1.2 channels by competitively displacing Ca V β subunits and exposing lysines to ubiquitination and by masking the endoplasmic reticulum export signals also found within the I-II loop.
• Galectin-1 deficiency leads to higher blood pressure (BP) because of the increased arterial Ca V 1.2 expression in mice.
• The infusion of Tat-e9c peptide that disrupts Ca V 1.2-galectin-1 interaction increases smooth muscle Ca V 1.2 currents, induces larger arterial contraction, and causes hypertension in rats.
• The smooth muscle-specific overexpression of galectin-1 by a single injection of AAV5-galectin-1 significantly reduces BP in spontaneously hypertensive rats.
What Are the Clinical Implications?
• Based on the negative modulation of galectin-1 in smooth muscle Ca V 1.2 channels, reduced galectin-1 protein contributes to the pathological Ca V 1.2 upregulation in hypertensive arteries.
• Given the effective regulation of BP by both Tate9c peptide and AAV5-galectin-1 in rats, using galectin- 
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Human internal mammary arteries were collected from patients undergoing coronary artery bypass surgeries, and human pulmonary arteries were collected from patients with heart transplant at the National Heart Center Singapore. This study was approved by the SingHealth Centralised Institutional Review Board (Reference No. 2004/033/C). Animal experiments were approved and performed in accordance with the guidelines of the Institutional Animal Care and Use Committee of National University of Singapore or the National Neuroscience Institute.
Statistics
Data were shown as mean±SEM. The Student t test was used to compare 2 groups, and 1-way ANOVA followed by the Bonferroni post hoc test was used for multiple group comparisons. The statistical significance of daily monitored blood pressure between peptide-infused Wistar Kyoto rats was analyzed by 2-way repeated-measures ANOVA. The association between Ca V 1.2 and Gal-1 in hypertensive arteries was quantified with the Pearson correlation coefficient. P≤0.05 was considered statistically significant.
RESULTS

Gal-1 Promotes Proteasomal Degradation of Ca V 1.2 Channels by Competitively Disrupting Ca V 1.2-Ca V β Interaction
Following from our previous report identifying the Gal-1-binding domain situated within the I-II loop of Ca V 1.2, 11 we now show that D457 and E459 are the critical amino acids for Gal-1 binding by glutathione-Stransferase pull-down assays ( Figure IA and IB in the online-only Data Supplement). For further validations, DE457/459AA substitutions, but not E458A, disrupted Ca V 1.2-Gal-1 interaction and abolished Gal-1-mediated reduction in Ca V 1.2 current density ( Figure IC through IE in the online-only Data Supplement). To determine Gal-1-specific inhibition of Ca V 1.2 channel activity, we showed that Gal-1 did not affect the Ca V 1. To further understand the negative modulation of Ca V 1.2 channel function by Gal-1, we first showed that GFP-Ca V 1.2 and Gal-1-DsRed were colocalized (Mander coefficient (M1, DsRed: GFP)=0.97; Figure IIA in the online-only Data Supplement) in human embryonic kidney 293 (HEK 293) cells cotransfected with ERoxBFP (a fluorescent endoplasmic reticulum marker 17 ). Confocal imaging showed that Gal-1-expressing cells displayed a lower signal for ER-localized Ca V 1.2 channels in comparison with Gal-1-negative cells ( Figure 1A) . By contrast, Gal-1-expressing cells treated with a proteasomal inhibitor, MG132, displayed similar levels of ER-localized Ca V 1.2 channels ( Figure 1A ). To validate this finding in native cells, immunostaining of cultured vascular smooth muscle cells expressing ERoxBFP showed that Ca V 1.2 channels and Gal-1 mainly colocalized in ER ( Figure 1B and Figure IIB in the online-only Data Supplement, M1=0.99), whereas the application of MG132 enhanced the level of ER-localized Ca V 1.2 channels (Figure 1B, Right) . Taken together, these results suggest that Gal-1 interaction with Ca V 1.2 channels retained them in the ER.
Next, we investigated the effects that Gal-1 has on the expression levels of total and plasma membrane-bound Ca V 1.2 channels, and our results showed that Gal-1 reduced both total and biotinylated surface Ca V 1.2 channels in HEK 293 cells ( Figure 1C and 1D) . However, in the presence of MG132, but not chloroquine (a lysosomal inhibitor; Figure 1C and 1D), the expression levels were restored, suggesting that the degradation of Ca V 1.2 proteins triggered by Gal-1 is dependent on the ubiquitinproteasome system, but not the lysosomal pathway. This finding was further supported by confocal imaging that, in comparison with Gal-1-negative cells, coexpression of Gal-1 resulted in lower surface expression of HA-Ca V 1.2 channels (M1=0.48; Figure IIB in the online-only Data Supplement) that could be reversed by MG132 ( Figure 1E ). In addition, whole-cell patch-clamp electrophysiological recordings of Ca V 1.2 channels demonstrated that MG132 could abolish Gal-1-mediated decrease in Ca V 1.2 current density ( Figure IIIA in the online-only Data Supplement). These results provided strong evidence that the reduction of Ca V 1.2 channel surface expression by Gal-1 was attributable to increased degradation of Ca V 1.2 channels through the ubiquitin-proteasome system. We determined the rate of degradation of the Ca V 1.2 channels after the application of cycloheximide (a protein translation inhibitor) and found that Gal-1 significantly accelerated the rate of degradation of Ca V 1.2 channels in transfected HEK 293 cells after 4 hours of cycloheximide treatment ( Figure IIIB in the online-only Data Supplement).
Because Ca V 1.2 channels are targeted for proteasomal degradation in the absence of the Ca V β subunit, 10 disruption of Ca V β binding by Gal-1 may be the prerequisite for the degradation of the channels. However, the mechanism by which Gal-1 downregulates Ca V 1.2 channel activity is unknown. Based on the colocalization of Ca V 1.2 channels and Gal-1 in ER ( Figure 1A and 1B Figure IIID and IIIE in the online-only Data Supplement). In addition, bound Gal-1 was not detected under vehicle or chloroquine treatment ( Figure IIID and IIIE in the online-only Data Supplement), suggesting that the Gal-1-Ca V 1.2 complex may be degraded together via the ubiquitin-proteasome system, and therefore the ratio of Ca V β 2a to Ca V 1.2 remained unaltered. In addition to Ca V β 2a , Gal-1 was also able to disrupt Ca V 1.2-Ca V β 3 interaction and downregulated the current density ( Figure  V in the online-only Data Supplement).
To further investigate how Gal-1 interferes with Ca V 1.2-Ca V β interaction, we cotransfected HEK 293 cells with Gal-1 at different molar ratios to Ca V 1.2 (Gal-1:Ca V 1.2=0, 0.5, 1, or 2), with or without MG132, and the results showed that Gal-1 dose-dependently reduced the levels of total and surface Ca V 1.2 channels ( Figure IVB in the online-only Data Supplement). It is notable that the amount of Ca V β 2a coimmunoprecipitated with Ca V 1.2 was also reduced in a dose-dependent manner ( Figure 1F and 1H). Nonetheless, we still needed to address the question on whether Gal-1 disrupted Ca V 1.2-Ca V β interaction through allosteric interference with Ca V β binding to Ca V 1.2 or that it could displace bound Ca V β from the channels. Here, we incu- Figure 1G and 1I). These results indicated that Gal-1 could displace the Ca V β subunit that was already bound to the Ca V 1.2. This ability of Gal-1 to disrupt Ca V 1.2-Ca V β interaction was further confirmed functionally because Gal-1 decreased Ca V 1.2 current densities in a dose-dependent manner ( Figure 1J and 1K).
Gal-1 Exposed Lysines Within Ca V 1.2 I-II Loop to Ubiquitination
Next, we examined the consequences on Ca V 1.2 channels after Gal-1 displaced Ca V β binding to the channels. First, we asked which specific lysines are required for polyubiquitination of Ca V 1.2 in the absence of Ca V β. To identify the lysine residues, we used the in silico prediction tool, UbPred, 18 to predict the potential ubiquitination sites along the entire Ca V 1.2 protein. As shown in Table V in the online-only Data Supplement, the lysines with high predictive scores are located in the I-II loop, II-III loop, and C terminus. However, the ubiquitination level of only HA-I-II loop, but not HA-II-III loop and C terminus, was markedly inhibited by Ca V β 2a (n=4, Figure 2A through 2D). To substantiate that the I-II loop lysines are sufficient for Ca V 1.2 ubiquitination, we used Ca V 1.2-Ca V 3.1 chimeric channels in which either the Ca V 1.2 I-II loop, II-III loop, or C terminus was substituted for the corresponding region in the Ca V β-independent Ca V 3.1 channel. The chimeric channels were named Ca V 3.1 -GCGGG , Ca V 3.1 -GGCGG , or Ca V 3.1 -GGGGC , respectively, and the biochemical properties were characterized in the presence or absence of Ca V β 2a subunits. The results showed that the ubiquitination level of Ca V 3.1 -GCGGG , but not Ca V 3.1 -GGCGG and Ca V 3.1 -GGGGC channels, was significantly enhanced in the absence of Ca V β 2a subunits (n=4, Figure 2E and 2F). These results clearly indicated that, in the absence of Ca V β subunit, the I-II loop was required and sufficient for Ca V 1.2 polyubiquitination, and is consistent with a recent report on ubiquitination of the Ca V 2.2 I-II loop. 19 To identify which of the 6 lysines within Ca V 1.2 I-II loop are important for ubiquitination, we categorized the first 3 lysines (K4, K10, and K17) and the last 3 lysines (K21, K29, and K54) into 2 groups based on the prediction scores and their positions in the I-II loop (Table V in the online-only Data Supplement). We generated substitutions of lysines for alanines in different combinations. The ubiquitination level of the various I-II loop mutants were examined in the presence or absence of Ca V β subunits. The constructs containing K4A, K10A, and K17A substitutions did not significantly reduce the level of ubiquitination (n=3, Figure VIIA in the onlineonly Data Supplement). In contrast, the K21A, K29A, or K54A single substitutions showed obvious decrease in ubquitination level by ≈22%, 52% or 55%, respectively (n=4, Figure VIIB and VIIC in the online-only Data Supplement). Furthermore, double or triple substitutions of K21/29A, K21/54A, K29/54A, or K21/29/54A led to a significant reduction of I-II loop polyubiquitination in comparison with K21A single substitution (P=0.035, 0.0012, or 0.044, respectively), but not K29A or K54A substitutions (n=4, Figure VIIB and VIIC in the online-only Data Supplement). These results suggested that K29 and K54 in the I-II loop are highly likely the dominant sites critical for Ca V 1.2 polyubiquitination. To further confirm the role of these lysines, the equivalent positions of K410, K416, K423, K427, K435, or K460 residues were mutated into alanines in different combinations in the full-length Ca V 1.2 channel. The Ca V 1.2 -K427/435/460A , but not Ca V 1.2 -K410/416/423A channels, showed a significant decrease in polyubiquitination in comparison with wildtype Ca V 1.2 channels (n=4, Figure 2G and 2H). Besides, the total expression level of Ca V 1.2 -K427/435/460A channel did not display significant differences in the presence or absence of Ca V β 2a subunits (P=0.8), whereas the total Ca V 1.2 -K410/416/423A channels were still markedly reduced without Ca V β subunits (P=0.04, n=3, Figure VIID and VIIE in the online-only Data Supplement). However, the surface expressions of all wild-type and mutant Ca V 1.2 channels were downregulated in the absence of Ca V β 2a subunits (n=3, Figure VIID Taken together, Gal-1 binding to the I-II loop displaced Ca V βbinding to the AID and thereby exposed K427, K435, and K460 to polyubiquitination.
To further validate the regulation of Ca V 1.2 channels by endogenous Gal-1, Gal-1 small interfering RNA was applied to knock down Gal-1 in smooth muscle A7r5 cells, which resulted in reduced ubiquitination level and increased total expression of Ca V 1.2 channels ( Figure IX in the online-only Data Supplement).
Gal-1 Binding Precludes Trafficking of Ca V 1.2 Channel Because of ER Export Signal Within the I-II Loop
Recently, the acidic residues within the C terminus of exon 9 were identified as the ER export signal of Ca V 1.2 Figure 3A) . This information raises a question on whether Gal-1 binding at the region is able to mask the ER export signal or, if not, whether the unmasked ER signal will counterbalance the reduction of the surface expression of Ca V 1.2 channels because of Gal-1 binding and ERAD degradation. To resolve these possibilities, alanine substitution of the Gal-1-binding sites, D457 and E459, were generated and these mutants did not significantly alter the current density of Ca V 1.2 channels (Figure X in the online-only Data Supplement). Next, we generated 2 Ca V 1.2 mutants carrying alanine substitutions of ER export signals, but retaining D457 and E459 residues, in ubiquitination-sensitive Ca V 1.2 -K410/416/423A and ubiquitination-resistant Ca V 1.2 -K427/435/460A channel backbones, and they are named Ca V 1.2 -K410/416/423A-ER and Ca V 1.2 -K427/435/460A-ER ( Figure 4A ), respectively. The Ca V 1.2 -K410/416/423A-ER channels displayed ≈30% reduction in current density in comparison with Ca V 1.2 -K410/416/423A channels ( Figure 3B and 3C ), suggesting this ER export signal played a role in channel trafficking to cell membrane. If there were a counterbalance between export and degradation, we would expect that Gal-1 interaction with Ca V 1.2 -K410/416/423A-ER channels would result in a larger decrease in current density, in comparison with the Gal-1 effect on wild-type channels. However, Gal-1 reduced the current density of Ca V 1.2 -K410/416/423A-ER channels by ≈50% ( Figure 3B and 3C) , which is similar to the effect of Gal-1 on wild-type Ca V 1.2 channels ( Figure IIIA in the online-only Data Supplement). These data suggest that Gal-1 binding may have masked the ER export signal, and this effect is mimicked by mutations of the ER export signal. However, mutations of ER export signals in Ca V 1.2 -K427/435/460A channels (which are resistant to ERAD degradation) did not significantly alter the current density ( Figure 3D and 3E), which may be because the β subunits are able to traffic highly accumulated Ca V 1.2 -K427/435/460A channels to ORIGINAL RESEARCH ARTICLE the cell membrane. In addition, Gal-1 did not affect the current density of Ca V 1.2 -K427/435/460A-ER channels ( Figure 3D and 3E), suggesting that mutations of ubiquitination sites, not the ER export signals, prevented Gal-1-mediated ERAD degradation of Ca V 1.2 channels. To rule out the possibility that this noninhibitory effect of Gal-1 on Ca V 1.2 -K427/435/460A-ER channels is attributable to weakened interactions between Gal-1 and Ca V 1.2 channels, co-IP experiments were performed to detect the interactions between Ca V 1.2 mutants and Gal-1. Our results showed that Gal-1 was able to bind to both Ca V 1.2 -K427/435/460A-ER and Ca V 1.2 -K410/416/423A-ER channels and also competitively replace Ca V β 2a subunits from these 2 Ca V 1.2 mutants (Figure 3F and 3G) . However, Gal-1 did not affect the total expression of Ca V 1.2 -K427/435/460A-ER channels, but significantly reduced the level of total Ca V 1.2 -K410/416/423A-ER channels ( Figure 3H and 3I) , These results imply that the inhibitory effects of Gal-1 on Ca V 1.2 channels are ascribed to increased channel degradation that was not counterbalanced by trafficking attributable to the ER export signal. In addition, in comparison with Ca V 1.2 -K410/416/423A channels, the total level of Ca V 1.2 -K410/416/423A-ER channels was not significantly reduced ( Figure 3H and 3I) , suggesting the ER export signals only affect trafficking, but not the total expression level of Ca V 1.2 channels. These results imply that the inhibitory effects of Gal-1 on Ca V 1.2 channels are attributable to increased channel degradation in conjunction with the masking of ER export signal.
Inverse Correlation of Gal-1 and Ca V 1.2 Protein Levels in Arteries of Hypertensive Rats and Humans
Next, we asked whether the negative modulation of Ca V 1.2 expression level by Gal-1 is linked to pathological upregulation of vascular Ca V 1.2 channels in hypertension. Consistent with a previous report, 21 we demonstrated that Ca V 1.2 protein level was markedly increased in aorta (n=7, P=0.025, Figure 5A through 5C) of spontaneously hypertensive rats (SHRs). It is gratifying that Gal-1 was significantly downregulated (P=0.004, Figure 4A through 4C) in SHR, which showed a negative correlation with Ca V 1.2 
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protein levels (r=-0.951, P=0.001; Figure 4D ). In addition, Ca V β 2 was significantly increased in aorta of SHR, whereas Ca V β 3 was similar to Wistar Kyoto rats ( Figure Figure 4H ). In addition, we found that inclusion of exon 9* in mesenteric arteries isolated from SHR is significantly increased ( Figure XIV in the online-only Data Supplement). This upregulation of exon 9*-containing Ca V 1.2 channels, which are not functionally affected by Gal-1, 11 may further accentuate overall Ca V 1.2 up-regulation under hypertensive conditions.
Gal-1 Downregulation by HypoxiaInducible Factor 1α in Hypertensive Human Pulmonary Artery
To define the molecular mechanism underlying Gal-1 downregulation in hypertensive artery, we focused on hypoxia-inducible factor 1α (HIF-1α), a transcription factor that has been shown to upregulate the transcription of Gal-1. Here, we found that hypoxia-induced HIF-1α upregulation enhanced Gal-1 expression and reduced surface and total Ca V 1.2 channels in A7r5 cells ( Figure 5A and 5B), which was reversed by Gal-1 small interfering RNA ( Figure 5A and 5B). It is striking that, in a hypertensive human pulmonary artery (Table VII in 
Gal-1 Deficiency Increases Blood Pressure in Mice
To assess a potential linkage between hypertension and Gal-1 downregulation, we measured the blood pressure of Gal-1 null (Lgals1 -/-) mice and found that Gal-1 deficiency increased systolic blood pressure by ≈21% (134±5.6 versus 111±3.6 mm Hg; Figure 6A ) and diastolic blood pressure by ≈31% (71.4±2.8 versus 54.5±4.1 mm Hg; Figure 6B ). Although the blood pressure was not increased to a hypertensive level, this result revealed that Gal-1 deficiency was sufficient to increase blood pressure in vivo. To further verify Gal-1 deficiency-induced hypertension, mesenteric arteries were freshly isolated for pressure myography. The [K + ] otriggered maximal vasoconstriction was significantly enhanced by ≈1.7-fold in Lgals1 -/-arteries ( Figure 6C  and 6D) . Furthermore, thoracic aorta was isolated for immunohistochemistry, and we found that the level 
Disruption of the Ca V 1.2-Gal-1 Interaction by Tat-e9c Infusion Increased Blood Pressure in Rats
The above in vitro studies clearly demonstrated that Gal-1 facilitated Ca V 1.2 degradation through competitively displacing Ca V β. Next, we examined how direct interference with Ca V 1.2-Gal-1 interaction may affect blood pressure. Here, we used the Tat-e9c peptide (Figure 7A ) that contains the 11-amino-acid TAT sequence fused to the 18-amino-acid peptide of the C-terminal end of exon 9 that included the Gal-1-binding site. Application of Tat-e9c, but not control Tat-e12c (TAT sequence fused to the 18-amino-acid peptide of exon 12 that forms the downstream Ca V 1.2 I-II loop), increased the levels of total and surface biotinylated Ca V 1.2 channels in isolated primary rat aortic smooth muscle cells ( Figure XVIIA . These results demonstrated that Tat-e9c was effective in disrupting the interaction between Gal-1 and Ca V 1.2. Using freshly isolated rat mesenteric arteries, we examined the role of Tat-e9c in arterial contractility. Application of Tat-e9c, but not Tat-e12c, to cultured mesenteric arteries, produced a significant increase in total Ca V 1.2 protein ( Figure XVIIE Figure 7D and 7E) were highly enhanced with Tat-e9c treatment. Tat-e9c-treated arteries were more sensitive to membrane depolarization arising from increasing K + concentrations. The EC 50 was 32.9 mmol/L K + for Tat-e9c-treated arteries and 42.7 mmol/L K + for Tat-e12c-treated arteries ( Figure 7E ). In addition, the maximal contractility in Tat-e9c-treated arteries was 15% higher than in Tat-e12c-treated arteries ( Figure 7E ). To further validate the ex vivo results by pressure myography and extend our findings to in vivo significance, we infused Tat-e9c or Tat-e12c (400 pmol·kg -1 ·min
) via the jugular veins by osmotic minipumps, and monitored the blood pressure >9 days. Our results revealed that, although the chronic delivery of Tat-e12c into rats maintained similar systolic blood pressure during the chronic delivery (115.9±2.0 mm Hg), in stark contrast, chronic delivery of Tat-e9c significantly increased systolic blood pressure on day 1, and reaching a peak on day 3 (148.6±3.7 mm Hg, P<0.0001; Figure 7F ). In addition, from day 4 onward, diastolic blood pressure in Tat-e9c-treated rats significantly exceeded that of Tat-e12c-treated rats (106.7±6.5 versus A and B, Western blots and quantifications of surface and total Ca V 1.2 channels, HIF-1α and Gal-1 in A7r5 cells under normoxia or hypoxia with transfection of nontarget siRNA or Gal-1 siRNA (n=4). C and D, Western blots and quantifications of total Ca V 1.2 channels, β 2 and β 3 subunits, HIF-1α and Gal-1 in nonhypertensive or hypertensive human pulmonary arteries (n=3, each sample has 2 replicates). Data were shown as mean±SEM. *P<0.05, #P<0.01 versus control group. Gal-1 indicates galectin-1; HIF-1α, hypoxia-inducible factor 1α; HTN, hypertensive; ns, nonsignificant; and siRNA, small interfering RNA.
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65.1±2.6 mm Hg, P<0.0001. Figure XIXA in the onlineonly Data Supplement). Following blood pressure measurements, the mesenteric arteries and thoracic aorta were processed and, Western blot analyses showed that total and biotinylated surface Ca V 1.2 channels were up-regulated by 2.8-and 4.4-fold, respectively, in mesenteric arteries of Tat-e9c-treated rats ( Figure 7G through 7I) and increased by a 2.1-and 2.9-fold, respectively, in thoracic aortas ( Figure XIXB through XIXD in the online-only Data Supplement). These results provide strong support that disruption of Ca V 1.2-Gal-1 interaction in vivo can increase blood pressure, while excluding any confounding effects attributable to direct knockdown of Gal-1. In addition, on examining the effect of Tat-e9c on cardiac function in rats, we showed that Tat 
Smooth Muscle-Selective Overexpression of Gal-1 by Delivery of AAV5-Gal-1 Decreased Blood Pressure in SHR
To explore whether Gal-1 overexpression could reduce blood pressure in vivo, the Gal-1 cDNA was subcloned into the AAV5 expression vector that contains a chimeric smooth muscle-specific enhancer/promoter (EnSM22α) 22 ( Figure 8A ). Intravenous injection of AAV5-Gal-1 (1×10 13 vector genomes/kg) resulted in selective -/-mice followed by normalization to DAPI intensity. n=3 mice, and 6 sections for each group were used for analysis. F, Representative confocal images of total Ca V 1.2 channels and Gal-1 in aorta from WT or Lgals1 -/-mice. Elastin autofluorescence was also detected to show the entire structure of aorta. For last merged image in rows 1 and 3, the channels for DAPI, Ca V 1.2 (AF594) and Gal-1 (AF647) were merged together. For the magnified images in row 2 and 4, only the channels for Ca V 1.2 (AF594) and Gal-1 (AF647) were merged together to show the colocalization of Ca V 1.2 channel and Gal-1 in smooth muscle. Scale bar: 20 μm. Data were shown as mean±SEM. * P<0.05, # P<0.01 versus control group. DAPI indicates 4ʹ,6-diamidino-2-phenylindole; DBP, diastolic blood pressure; Gal-1, galectin-1; L, lumen of aorta. ROI, region of interest; SBP, systolic blood pressure; and WT, wild type.
expression of Flag-tagged Gal-1 in thoracic aorta and mesenteric artery ( Figure 8B ) and remarkably increased Gal-1 expression (P=0.0027) and decreased Ca V 1.2 protein level (P=0.03) in thoracic aorta of SHR ( Figure 8C and 8D). It is notable that no exogenous Flag-Gal-1 was detected in rats injected with the control AAV5-GFP ( Figure 8B and 8C) . The blood pressure recorded by telemetry showed that AAV5-Gal-1-treated SHR exhibited a decrease in systolic blood pressure ( Figure 8E ), diastolic blood pressure ( Figure 8G ), and mean arterial pressure (mean arterial pressure; Figure 8I ) at day 2 after virus injection, reaching a maximal reduction of 27 mm Hg (P<0.001; Figure 8F ), 20 mm Hg ( Figure 8H ), and 23 mm Hg (Figure 8J ), respectively, from day 7 onward. It is significant that the blood pressure in AAV5-Gal-1-treated SHRs remained reduced for 30 days ( Figure 8E through 8J), indicating a stable and long-term effect of AAV5-Gal-1 delivery in reducing blood pressure.
DISCUSSION
Because L-type Ca V 1.2 calcium channels are the major pathway of Ca 2+ entry to initiate smooth muscle contraction, dysregulation of these channels has been implicated to contribute to hypertension. [23] [24] [25] Evidence to support this proposal is reports showing the marked increase in Ca V 1.2 channels in arteries of genetic and salt-sensitive rat models of hypertension, 21, 26, 27 and that specific deletion of smooth muscle Ca V 1.2 channels in mice reduced arterial blood pressure. 5 Although increased expression of Ca V 1.2 channels in smooth muscles has been observed in hypertension, the underlying ] o for the effects of Tat-e12c or Tat-e9c on the contractility of mesenteric arteries. Data were shown as mean±SEM. *P<0.05, #P<0.01 versus control group. F, Daily systolic blood pressures in rats before, during, or after 9-day Tat-e9c infusion (n=6 for each group). Osmotic minipumps were implanted via jugular vein at day 0. Tat-e9c-treated rats exhibited an increase in systolic blood pressure at day 1 after Tat-e9c infusion and reaching to a peak at day 3 (148.6±3.7 mm Hg; versus 115.9±2.0 mm Hg for Tat-e12c group). Data were analyzed by 2-way repeated measures ANOVA (F(1, 10)=492.350, P<0.0001 for treatment; F(11, 110)=37.410, P<0.0001 for time; F(11, 110)=23.310, P<0.0001 for interaction). G through I, Western blots and quantifications of biotinylated surface and total Ca V 1.2 channels in mesenteric arteries in Tat-e12c-or Tat-e9c-treated rats (n=6). α-Smooth muscle actin was used as the loading control. Data were shown as mean±SEM. *P<0.05, #P<0.01 versus Tat-e12c group. BP indicates blood pressure; and SM, small muscle. Figure 4E ). Here, we delineated the detailed mechanisms for the negative modulation of Ca V 1.2 channels by Gal-1, whereby Gal-1 binding to D457 and E459 residues of the C-terminal end of exon 9 promotes proteasomal degradation of Ca V 1.2 channels by displacing Ca V β subunit binding to AID and exposing the channels to polyubiquitination and ERAD degradation. However, this pathway precludes trafficking arising from the embedded ER export signal localized within the C terminus of exon 9 (Figures 1 through 3) as Gal-1 binding would have masked it. In addition, we provided significant evidence of a strong negative correlation between the expression levels of smooth muscle Gal-1 and Ca V 1.2 channel proteins in arteries from both SHR and hypertensive patients (Figure 4) . It is more important that we established Gal-1 as a crucial molecular switch to regulate arterial constriction and blood pressure through promoting Ca V 1.2 channel degradation in smooth muscles (Figure 6 ). Our findings were further substantiated by results that demonstrate that direct interference with Ca V 1.2-Gal-1 interaction by Tat-e9c peptide significantly increased arterial constriction and myogenic tone in isolated rat mesenteric arteries and elevated blood pressure in rats (Figure 7) . In stark contrast, reduction of Ca V 1.2 channel expression by selective overexpression of Gal-1 in smooth muscle reduced blood pressure in SHR (Figure 8 ).
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In patients with early-onset preeclampsia, usually with clinically recognizable features, such as hypertension and proteinuria, Gal-1 protein levels in serum and 13 vector genomes/kg, n=4), from day 7 onward, SHR subject to single injection of AAV5-Gal-1 (1×10 13 vector genomes/kg, n=3) reached a maximal reduction of the systolic blood pressure (SBP) at ≈27 mm Hg (E and F), the diastolic blood pressure (DBP) at ≈20 mm Hg (G and H) and the mean arterial pressure (MAP) at ≈23 mm Hg (I and J), respectively, and remain reduced until day 30. Mean SBP (F), DBP (H), and MAP (J) stand for the average blood pressure from day 7 to day 30. Data were shown as mean±SEM. *P<0.05, ***P<0.001 versus AAV5-GFP group. Gal-1 indicates galectin-1; GFP, green fluorescent protein; IRES, Internal Ribosome Entry Site; MA, mesenteric artery; SHR, spontaneously hypertensive rat; and WPRE, Woodchuck hepatitis posttranscriptional regulatory. expression in placental villi were reduced. 16 Given our results, the reduction in Gal-1 might lead to remodeling of maternal spiral arteries and abnormal uteroplacental artery blood flow, 16 hypothetically arising from increased Ca V 1.2 expression. Moreover, our data support the findings of increased pulmonary artery pressure in Gal-1 null (Lgals1 -/-) mice when exposed to acute hypoxia 15 and gestational hypertension in pregnant Lgals1 -/-mice. 16 These results suggest that downregulation of Gal-1 may correspond to the pathogenesis of hypertension, consistent with our findings that Gal-1 protein level is reduced in arteries of SHR and in mammary arteries from human patients with hypertension ( Figure 4) . However, our study also raises the question of how Gal-1 is downregulated in smooth muscle under hypertension. HIF-1α, a well-known transcription factor, has been reported to upregulate the mRNA and protein levels of Gal-1 in 4 colorectal cancer cell lines, with 2 hypoxia-responsive elements found in the promoter of Gal-1. 31 It is more important that, in smooth musclespecific HIF-1α knockout mice, both pulmonary arterial pressure 32, 33 and systolic blood pressure 34 were increased through upregulating phosphorylation of myosin light chain and downregulating peroxisome proliferatoractivated receptor-γ-angiotensin II receptor type 1 axis, respectively, because of the lack of smooth muscle HIF-1α. In addition, HIF-1α was also downregulated in isolated pulmonary smooth muscle cells from patients with idiopathic pulmonary hypertension. 32 These studies are consistent with our findings that both HIF-1α and Gal-1 protein levels were downregulated in hypertensive human pulmonary arteries ( Figure 5 ), which indicates that HIF-1α may function as a signaling pathway upstream of Gal-1 in smooth muscle and then contribute to hypertension by acting on Ca V 1.2 channels.
Calcium channel blockers have been clinically used to lower blood pressure, but calcium channel blocker treatment has also been reported to be associated with increased risk of myocardial infarction or heart failure in hypertensive patients with cardiac function impairment. [35] [36] [37] Gal-1 was shown to selectively reduce the current density of Ca V 1.2 channels, but not the other 3 paralogous L-type calcium channels (Figure IF through II in the online-only Data Supplement), such as Ca V 1.3 channels that are highly expressed in the sinoatrial node and are essential for the generation of cardiac pacemaker activity and control of heart rhythm. 38 Therefore, antihypertensive therapies through augmenting Ca V 1.2-Gal-1 interaction using gene therapy or by intravenous injection of Gal-1 protein may provide an alternative approach for hypertension treatment with reduced cardiac side effects. Alternatively, interfering with Ca V 1.2-Gal-1 coupling could selectively increase blood pressure in patients with clinical conditions in which a drastic drop in blood pressure could be fatal.
In summary, our study showed that Gal-1, a protein downregulated in hypertensive arteries, reduces Ca V 1.2 protein level by enhancing polyubiquitination of lysines embedded within the Ca V 1.2 I-II loop that subsequently leads to degradation via the ubiquitin-proteasome system. Molecularly, we have identified: (1) the critical lysine residues important for polyubiquitination; (2) the aspartate and glutamate residues for Gal-1 binding; (3) the mutually exclusive binding of Ca V β and Gal-1 to the I-II loop of the Ca V 1.2 channel; and (4) when Gal-1 binds, it masked the ER export signal, retained the channels in the ER and after the displacement of Ca V β are subject to ERAD degradation. Targeting Gal-1 by either overexpression in blood vessels or by Tat-e9c peptide infusion to specifically disrupt Ca V 1.2-Gal-1 interaction is potentially a direct and efficient approach to regulate blood pressure. These approaches may open new avenues in developing novel therapeutics for treatment of hypo-or hypertension, either through gene or protein therapy targeting Gal-1, or by discovering stabilizers of Ca V 1.2-Gal-1 interaction.
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